A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
A Phase II Clinical Study to Evaluate the Safety and Efficacy of SKB571 for Injection as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yina Diao
- Phone Number: 028-67252634
- Email: diaoyina@kelun.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Pulmonary Hospital
-
Contact:
- Shengxiang Ren
- Phone Number: 021-65115006-3051
- Email: harry_ren@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
- Participants with histologically or cytologically confirmed NSCLC.
- Locally advanced or metastatic NSCLC with MET Abnormalities that has progressed after standard therapy.
- At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose.
- Life expectancy ≥ 3 months as assessed by the investigator.
- Adequate organ and bone marrow function.
- Male and female participants must agree to use highly effective methods of contraception during the study treatment period.
- Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.
Exclusion Criteria:
- Participants with known active central nervous system (CNS) metastasis, and/or carcinomatous meningitis, brainstem metastasis, metastases to spinal cord, or spinal cord compression.
- Participants with other malignant tumors within 3 years prior to the first dose.
- Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
- Presence of severe and/or uncontrolled concomitant diseases.
- Participants with a history of interstitial lung disease (ILD) or a history of non-infectious pneumonitis.
- Clinically severe lung damage due to complications of lung disorder.
- Risk of esophagotracheal fistula or esophagopleural fistula, or tumor invasion or compression of surrounding vital organs and blood vessels.
- Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.
- Known active pulmonary tuberculosis.
- Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.
- Active hepatitis B and hepatitis C.
- Positive test for human immunodeficiency virus (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
- Known allergy or hypersensitivity to SKB571 or its excipients; or a history of severe allergy to other monoclonal antibodies.
- Participants who have undergone major surgery within 4 weeks before the first dose or are expected to require major surgery during the study.
- Serious infection within 4 weeks before the first dose.
- Participants who have received systemic corticosteroid therapy with > 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose of study treatment.
- Participants who have received a live vaccine within 30 days before the first dose, or plan to receive a live vaccine during the study.
- Pregnant or breastfeeding women.
- Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors.
- Any condition that, in the investigator's opinion, interferes with the evaluation of study treatment, participant safety, or interpretation of study results, or any other condition that the investigator deems unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SKB571 monotherapy
|
SKB571 for injection is administered every 3 weeks(Q3W) .
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AE
Time Frame: Up to 24 months
|
Incidence and severity of adverse events (AEs)
|
Up to 24 months
|
|
ORR
Time Frame: Up to 24 months
|
Objective response rate (ORR) assessed by the investigator as per RECIST v1.1.
|
Up to 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS
Time Frame: Up to 24 months
|
Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.
|
Up to 24 months
|
|
DOR
Time Frame: Up to 24 months
|
Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.
|
Up to 24 months
|
|
OS
Time Frame: Up to 24 months
|
Time from start of treatment to death due to any reason.
|
Up to 24 months
|
|
DCR
Time Frame: Up to 24 months
|
Disease control rate (DCR) (assessed by the investigators as per RECIST v1.1)
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SKB571-Ⅱ-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.